Login
Search
Search
0 Dates
2025
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
CPC 2025
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Persuing ventricular-arterial coupling: Proposing a new cut-off of TAPSE/sPAP to identify patients with pulmonary hypertension after intermediate-high risk pulmonary embolism
Session:
SESSÃO DE COMUNICAÇÕES ORAIS 02 – HIPERTENSÃO PULMONAR: DESENVOLVIMENTOS NA ESTRATIFICAÇÃO DE RISCO, DIAGNÓSTICO E TRATAMENTO
Speaker:
Julien Lopes
Congress:
CPC 2025
Topic:
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
Theme:
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
Subtheme:
21.3 Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure – Diagnostic Methods
Session Type:
Comunicações Orais
FP Number:
---
Authors:
Julien Lopes; Mariana Caetano Coelho; Bárbara Lacerda Teixeira; André Grazina; João Reis; Ana Galrinho; Duarte Cacela; Rúben Ramos; Melanie Ferreira; Rui Cruz Ferreira; Luís Almeida Morais
Abstract
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Aptos,sans-serif"><strong>Introduction</strong> – Pulmonary hypertension (PH) remains a potential long-term complication following pulmonary embolism (PE). Right heart catheterization (RHC) is the gold-standard for the diagnosis while echocardiography is often used as a non-invasive screening tool. The ventricular-arterial coupling accessed by echocardiography in the form of TAPSE/sPAP ratio is increasingly used as an add-on to other echocardiography parameters to better predict the probability of PH. This study aimed to evaluate the predictive power of echocardiographic parameters to detect PH in patients with intermediate-high risk PE submitted to catheter-directed therapy (CDT).</span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Aptos,sans-serif"><strong>Methods</strong> – Patients with intermediate-high risk PE submitted to catheter-directed therapy in a tertiary centre are submitted to a multimodality evaluation at 3 to 6-month follow-up to screen for PH. Patients were divided in two groups according to the presence of pre-capillary PH (mPAP >20 mmHg, PVR > 2 WU and PCWP < 15 mmHg in RHC) and echocardiographic parameters were analysed to assess their power to predict PH. </span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Aptos,sans-serif"><strong>Results</strong> – From the 78 patients, 42 completed the follow-up and were included in the analysis (median age 59 years [IQR 47-73 years], 57,1% female). 20 patients (47,6%) were diagnosed with PH by RHC at 3-6 month follow-up. Echocardiographic parameters of the right heart that were significantly different between the two groups were the presence of tricuspid regurgitation (p=0,01) and the TAPSE/sPAP ratio (p= 0,03). Peak tricuspid regurgitation velocity (p=0,169) and RVOT acceleration time (p=0,520) showed no statistically significant differences between the two groups. The ROC curve analysis of TAPSE/sPAP showed the best cut-off value of 0,64 (p=0,001, AUC 0,752, Sensibility 53%, Specificity 93%) when comparing with the guideline recommended cut-off of 0,55 (p=0,389, AUC 0,577, Sensibility 20%, Specificity 95%). A logistic regression model showed a OR 2,15 (p=0,017) in predicting PH for each increase of 0,1 in TAPSE/sPAP ratio. </span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Aptos,sans-serif"><strong>Conclusion</strong> – In our study, for patients after intermediate-high risk PE, the ventricular-arterial coupling accessed by echocardiogram (TAPSE/sPAP) showed to be most valuable echocardiographic parameter to predict the presence of PH 3 to 6 months of effective anticoagulation. However, the optimal cut-off may be outdated taking into account the most recent hemodynamic threshold for the diagnosis of PH. In our cohort, a higher value of TAPSE/sPAP ratio seems to be a better predictor of PH. </span></span></p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site